close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

8.460 -0.130 (-1.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Novavax, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Novavax Inc. (NASDAQ: NVAX) Near the Top of Equities by Percentage Gain on 7/10
Via Investor Brand Network
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
Novavax Inc. (NASDAQ: NVAX) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Rises in After-Hours Trading Following Major UK Contracts and FDA Progress
Via AB Newswire
Topics Economy
GameStop Raises $2.14 Billion, Meme Stocks Buzz Fuels Gains Watch: GME, PRSO, DYAI, VTAK, AMC
Via AB Newswire
Top 4 Large-Cap Stocks With Major Short Interest
As meme stock mania continues, stocks with high short interest like Novavax, Upstart, C3.ai, and Comstock Resources may attract renewed interest. 
Via MarketBeat
Spotlight June 2024: NASDAQ Stocks Under $2 Achieving Major Milestones TELL, DYAI, PRSO, SPEC, GME
Via AB Newswire
Topics Energy
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
Novavax Stock’s Recent Surge and Future Potential
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance. 
Via MarketBeat
Topics Economy
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
Peraso Inc. (NASDAQ: PRSO) Announces Paradigm-Shifting mmWave Wi-Fi Advancements with Phased Array Antenna Technology
Via AB Newswire
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
From Shah Capital
Via GlobeNewswire
5 Meme Stocks With a High Short Interest
Keith Gill, aka RoaringKitty, resurfaces on Twitter, triggering a surge in GameStop and AMC Entertainment shares amid remarkable trading volume. 
Via MarketBeat
Topics Economy
Shah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting
From Shah Capital
Via GlobeNewswire
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
Shah Capital nominates two highly qualified independent director candidates for Novavax
From Shah Capital
Via GlobeNewswire
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
Via MarketBeat
Topics Cannabis
Exploring Stocks with High Short Interest: INBS, BLNK, BYND, NVAX, PLUG
Via AB Newswire
Topics Electric Vehicles
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with 
Via MarketBeat
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea 
Via MarketBeat
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death Economy
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
MarketBeat Week in Review – 1/30 - 2/3
The markets are trending lower to end the week. It’s hard to figure out the markets after the blockbuster job report, but the MarketBeat team gave it a shot 
Via MarketBeat
Topics Artificial Intelligence Earnings Economy
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today